{
    "Trade/Device Name(s)": [
        "Vivatmo pro"
    ],
    "Submitter Information": "Bosch Healthcare Solutions GmbH",
    "510(k) Number": "K233775",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXA"
    ],
    "Summary Letter Date": "November 17, 2023",
    "Summary Letter Received Date": "November 24, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3080"
    ],
    "Regulation Name(s)": [
        "Breath Nitric Oxide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "other"
    ],
    "Analyte(s)": [
        "Fractional exhaled nitric oxide (FeNO)"
    ],
    "Specimen Type(s)": [
        "Human breath"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Vivatmo pro"
    ],
    "Method(s)/Technology(ies)": [
        "Nitric oxide measurement"
    ],
    "Methodologies": [
        "Breath analysis"
    ],
    "Submission Type(s)": [
        "Instrument",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Vivatmo pro portable device for measuring fractional exhaled nitric oxide in breath as an adjunct in asthma management.",
    "Indications for Use Summary": "Measurement of fractional exhaled nitric oxide (FeNO) in breath to assess therapeutic response in asthma patients with elevated FeNO levels, used as adjunct to clinical assessment in children (7-17 years) and adults (18+), in point-of-care settings under professional supervision.",
    "fda_folder": "Toxicology"
}